Pepgen appoints kasra kasraian, phd, as chief technology officer

Boston--(business wire)--pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of kasra kasraian, phd, as chief technology officer (cto). dr. kasraian brings over 25 years of experience in product and process development, cmc strategy, and technical operations, spanning small and large molecules, as.
PEPG Ratings Summary
PEPG Quant Ranking